Lumibird SA (LBIRD) AI Stock Analysis

• Market Cap: €505.96M
• Dividend Yield: N/A
• Average Volume (3M): 32.82K
• Price to Earnings (P/E): 20.7
• Beta (1Y): 0.65
• Revenue Growth: 5.66%
• EPS Growth: 66.79%
• Country: FR
• Employees: 1,027
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.22
• Shares Outstanding: 22,466,883
• 10 Day Avg. Volume: 22,637
• 30 Day Avg. Volume: 32,817
• PEG Ratio: -1.93
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.98
• P/FCF Ratio: 18.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.06
• Revenue Forecast (FY): €252.80M

• Rating: 73 Outperform
• Price Target: €26.00 ▲(22.07% Upside)
• Action: Upgraded Date: 10/23/25
• Date: Action: Upgraded 10/23/25

Lumibird SA's overall stock score is driven by strong technical indicators and solid financial performance, despite high valuation concerns. The company's operational efficiency and positive cash flows are significant strengths, while the high P/E ratio suggests potential overvaluation.

Positive Factors

Cash generation

Robust operating cash flows and improved free cash flow indicate durable ability to fund operations, R&D and selective M&A without relying solely on markets. This cash generation supports reinvestment and financial flexibility over the next several quarters.

Diversified end markets & partnerships

Exposure to defense, medical and industrial markets plus strategic partnerships provides revenue diversification and access to large, recurring contracts. This mix reduces single-market cyclicality and strengthens multi-quarter revenue visibility and commercial stickiness.

Operational efficiency

Sustained EBIT/EBITDA margins show the company manages operating expenses effectively despite margin headwinds. This operational efficiency supports cash flow resilience and reinvestment capacity in a capital-intensive photonics business over the medium term.

Negative Factors

Margin pressure

Declining gross and net margins point to rising input costs or pricing pressure that can persist absent stronger pricing power or cost reductions. Prolonged margin compression would erode profitability, ROE and internal funding for growth across upcoming quarters.

Increasing leverage

A rising debt-to-equity trend increases financial leverage and interest burdens, reducing strategic flexibility. Higher leverage leaves less room to absorb cyclical shocks or fund additional R&D/acquisitions without increasing refinancing risk over the medium term.

High capital expenditure burden

Persistent high capex requirements for manufacturing and R&D constrain free cash flow conversion and limit funds available for debt reduction or shareholder returns. Continued capex intensity may necessitate external funding or slower deleveraging over several quarters.

Lumibird SA Business Overview & Revenue Model

Company Description

Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, high power laser diodes, fiber lasers, fiber amplifiers and components, photonics solutions for time-of-flight lidar and range-finding, and doppler lidar systems for wind measurement. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The Medical division provides medical and ophthalmological solutions from diagnosis to laser treatment. The company was founded in 1970 and is headquartered in Lannion, France.

How the Company Makes Money

Lumibird generates revenue primarily through the sale of its laser systems and components to various industries. The company has established key revenue streams from both product sales and ongoing service contracts for maintenance and support. Additionally, Lumibird benefits from strategic partnerships with major players in the defense and healthcare sectors, which provide access to larger contracts and collaborative projects. Their focus on innovation and R&D also leads to the development of new products, contributing to long-term revenue growth.

Lumibird SA Financial Statement Overview

Summary

Lumibird SA demonstrates strong operational efficiency and moderate financial stability. The income statement shows pressure on margins, but the balance sheet maintains a healthy equity ratio. Positive cash flows highlight the company's ability to support operations and growth.

Income Statement

Lumibird SA's income statement shows a stable revenue base with a slight increase from 2023 to 2024. Gross profit margin has slightly decreased over the years, indicating rising costs or pricing pressure. The net profit margin has declined from 2023 to 2024, suggesting challenges in maintaining profitability. However, EBIT and EBITDA margins remain decent, reflecting operational efficiency in managing expenses.

Balance Sheet

The balance sheet of Lumibird SA reflects moderate financial stability. The debt-to-equity ratio is manageable, though it has slightly increased over the years, indicating a rising reliance on debt. The equity ratio is stable, ensuring a sound capital structure. Return on equity has decreased, which may concern investors regarding the effectiveness of equity use.

Cash Flow

Lumibird SA's cash flow statement indicates strong operating cash flows, showing the company's ability to generate cash from its core operations. The free cash flow has improved from previous years but remains a concern due to high capital expenditures. The operating cash flow to net income ratio is robust, reflecting efficient cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	217.63M	210.06M	206.55M	194.29M	162.47M	129.50M
Gross Profit	20.78M	16.06M	128.11M	15.36M	18.49M	13.24M
EBITDA	39.19M	31.03M	27.31M	32.09M	31.81M	17.96M
Net Income	10.73M	5.70M	7.13M	11.35M	13.86M	5.64M
Balance Sheet
Total Assets	435.94M	429.80M	405.25M	372.04M	347.62M	305.43M
Cash, Cash Equivalents and Short-Term Investments	71.26M	71.14M	56.20M	61.68M	97.13M	80.33M
Total Debt	165.85M	161.06M	145.08M	114.18M	112.03M	88.31M
Total Liabilities	236.13M	231.79M	211.95M	178.61M	166.29M	141.35M
Stockholders Equity	196.03M	198.01M	193.30M	193.44M	181.33M	164.09M
Cash Flow
Free Cash Flow	5.13M	11.41M	-4.89M	-28.02M	6.47M	747.00K
Operating Cash Flow	27.26M	34.37M	20.67M	1.43M	26.57M	13.12M
Investing Cash Flow	-21.64M	-22.84M	-46.15M	-29.34M	-28.63M	-67.14M
Financing Cash Flow	2.13M	3.39M	21.69M	-7.89M	18.20M	84.76M

Lumibird SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:LBIRD, the sentiment is Positive. The current price of 21.3 is below the 20-day moving average (MA) of 22.79, below the 50-day MA of 22.51, and above the 200-day MA of 19.67, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 61.98 is Neutral, neither overbought nor oversold. The STOCH value of 73.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:LBIRD.

Lumibird SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LBIRD	73 Outperform	€505.96M	20.73	5.51%	―	5.66%	66.79%
ALDLT	66 Neutral	€329.30M	7.85	11.71%	2.10%	-1.89%	-3.39%
EXE	66 Neutral	€243.63M	14.82	―	3.00%	-10.58%	-47.82%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%